Pharmacological studies with Cetrorelix (SB-75), a potent antagonist of luteinising hormone-releasing hormone

European Journal of Cancer Part A

Volumn 32, Issue 9, 1996, Pages 1574-1579

  Reissmann, Th ^a   Klenner, Th ^a   Deger, W ^a   Hilgard, P ^a   McGregor, G P ^b   Voigt, K ^b   Engel, J ^a  

^a Ctrl Res and Devmt ASTA M   (Germany)

^b NONE

Author keywords

DMBA mammary carcinoma; Hormone suppression; LH RH antagonist; Slow release formulations

Indexed keywords

CETRORELIX; D 20762; DIMETHYLBENZ[A]ANTHRACENE; GONADORELIN ANTAGONIST; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030217853     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00138-4     Document Type: Article

References (26)

1. 1. Schally AV, Kastin AJ, Arimura A. Hypothalamic FSH and LH-regulating hormone: structure, physiology and clinical studies. Fertil Steril 1971, 22, 703-721.
2. 2. Lemay A, Maheux R, Faure N, Jean C, Fazekas ATA. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (buserelin) as new therapeutic approach for endometriosis. Fertil Steril 1984, 41, 863-872.
3. 3. Mansfield MJ, Beardsworth DE, Loughlin JS, et al. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. N Engl J Med 1983, 309, 1286-1292.
4. 4. Furr BJA, Milsted RAV. Use of analogues of LH-RH for treatment of cancer. Endocrine Mngmt Cancer 1982, 2, 17-27.
5. 5. Jackson MI, Matthews MJ, Diver JMJ. LH-RH analogues in the treatment of cancer. Cancer Treat Rev 1989, 16, 161-175.
6. 6. Williams G, Kerle DJ, Roe SM, Yeo T, Bloom SR. Results obtained in the treatment of prostate cancer patients with Zoladex. EORTC Genitourinary Group Monograph 2, Part A. Therapeutic Principles in Metastatic Prostatic Cancer. New York, Alan R. Liss, 1985, 287-295.
7. 7. Schally AV, Bajusz S, Redding TW, Zalatnai A, Comaru-Schally AM. Analogs of LH-RH: the present and the future. In Vickery BH, Lunenfeld V, eds. GnRH Analogs in Cancer and in Human Reproduction, Basic Aspects. Kluwer, Dordrecht, Vol. 1, 1989, 5-31.
8. 8. Hahn DW, McGuire JL, Vale WW, Rivier J. Reproductive/ endocrine and anaphylactoid properties of an LH-RH-antagonist, ORF-18260 (Ac-D-Nal(2)1, 4FDPhe2, D-Trp3, D-Arg6)-GnRH. Life Sci 985, 37, 505-514.
9. 9. Schmidt F, Sundaram K, Thau RB, Bardin CW. (Ac-D-Nal(2)1, 4FD-Phe2, D-Trp3, D-Arg6)-LH-RH, a potent antagonist of LH-RH, produces transient edema and behavioral changes in rats. Contraception 1984, 29, 283-289.
10. 10. Smith RD, Edgren RA. Elevated blood pressure following LH-RH antagonists in rats. Contraception 1982, 25, 395-403.
11. 11. Rivier J. Novel antagonists of GnRH: a compendium of their physiochemical properties, activities, relative potencies and efficacy in humans. In Lunenfeld B, Insler V, eds. GnRH Analogues -The State of the Art 1993. London, Parthenon, 1993.
12. 12. Pavlou S, Wakefield G, Schlechter NL. Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men. J Clin Endocrinol Metab 1989, 68, 446-53.
13. 13. Bajusz S, Csernus VJ, Janaky T, Bokser L, Fekete M, Schally AV. New antagonists of LH-RH. Int J Peptide Res 1988, 32, 425-435.
14. 14. Bajusz S, Kovacs M, Gazdag M, et al. Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects. Proc Natl Acad Sci USA 1988, 85, 1637-1641.
15. 15. Redding TW, Schally AV. Suppression of the pituitary-gonadal axis in nude mice by continuous administration of LH-RH agonists and antagonists. The Endocrine Society, 71st Annual Meeting 1989, Seattle, Washington, 192, No. 680.
16. 16. Reissmann T, Hilgard P, Harleman JH, Engel J, Schally AV, Comaru-Schally AM. Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone. J Cancer Res Clin Oncol 1992, 118, 44-49.
17. 17. Druckrey H, Steinhoff D, Nakayama M, Preussmann R, Anger K. Experimentelle Beiträge zum Dosis-Problem in der Krebs-Chemotherapie und zur Wirkungsweise von Endoxan. Dtsch Med Wschr 1963, 88, 651.
18. 18. Csernus VJ, Szende B, Groot K, Redding TW, Schally AV. Development of radioimmunoassay for a potent luteinizing hormone-releasing hormone antagonist. Drug Res 1990, 40, 111-118.
19. 19. Fekete M, Bajusz S, Groot K, Csernus VJ, Schally AV. Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor-binding ability to rat pituitary and human breast cancer membranes. Endocrinology 1989, 124, 946-955.
20. 20. Gonzales-Barcena D, Vadillo-Buenfil M, Garcia Procel E, et al. Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75). Eur J Endocrinol 1994, 131, 286-292.
21. 21. Szende B, Srkalovic G, Groot K, Lapis K, Schally AV. Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75. J Natl Cancer Inst 1990, 82, 513-517.
22. 22. Srkalovic G, Bokser L, Radulovic S, Korkut E, Schally AV. Receptors for Luteinizing Hormone-Releasing Hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75. Endocrinology 1990, 127, 3052-3060.
23. 23. Weinbauer GF, Nieschlag E. Evaluation of the antigonadotropic activity of different GnRH antagonists in the non-human primate. Gynecol Endocrinol 1990, 4, 21.
24. 24. Weinbauer GF, Nieschlag E. LH-RH antagonists: state of the art and future perspectives. Rec Res Cancer Res 1992, 124, 113-136.
25. 25. Behre HM, Böckers A, Schlingheider A, Nieschlag E. Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist Cetrorelix (SB-75) in normal men. Clin Endocrinol 1994, 40, 241-248.
26. 26. Gonzalez-Barcena D, Vadillo-Buenfil M, Gomez-Orta F, et al. Responses to the antagonistic analog of LHRH (Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. The Prostate 1994, 24, 84-92.